Iovance Biotherapeutics is one of the early big winners from ASCO. The firm announced updates from ongoing clinical trials including new interim data from studies of patients with advanced cervical cancer and advanced melanoma.
Health care instrument maker Agilent is getting hammered Wednesday following a worse-than-expected earnings report for the company's second fiscal quarter. The company's outlook for the rest of the year made matters worse.
Solid Biosciences shares were crumbling on Tuesday after the firm announced its first-quarter results and an update to its midstage Duchenne muscular dystrophy trial.
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference (May 31 to June…
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Mylan released mixed first-quarter financial results before the markets opened on Tuesday, and share plunged afterward.
Osmotica Pharma shares jumped on Tuesday after the firm announced results from its late-stage trial for the treatment of ptosis (droopy eyelid).
Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to be lower than a year ago.
Cytokinetics shares took a step back on Monday after the firm announced that its midstage trial for ALS failed to meet expectations.
It’s no simple task for a biotech giant to try to sell itself to investors as a value stock. That has been the case for some time when it comes to Gilead Sciences, Inc.…
Nabriva Therapeutics shares dropped sharply on Wednesday after the firm received a warning from the FDA for the New Drug Application seeking marketing approval of Contepo (fosfomycin).
Hermispherx Biopharma shares shot up on Tuesday after the firm announced significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center.
